Analyst consensus rating
Regeneron Pharmaceuticals Analyst Rating: Buy
Direct answer
Regeneron Pharmaceuticals's consensus rating is Buy.
27 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $863.93.
Forecast evidence checked October 19, 2026.
Get free Regeneron Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $790.74
- Average price target
- $863.93
- High price target
- $1,030.00
- Low price target
- $730.00
- Low target gap
- -7.7%
- Target upside
- +9.3%
- High target gap
- +30.3%
- Target range width
- 37.9%
- Consensus rating
- Buy
- Analysts
- 27
- Evidence date
- October 19, 2026
- Valid through
- October 26, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals has a verified Buy consensus. The same dataset has an average price target of $863.93.
How far are Regeneron Pharmaceuticals's low and high targets from the recorded price?
The low target implies -7.7%, while the high target implies +30.3%.
How many analysts are included in Regeneron Pharmaceuticals's consensus?
The verified consensus includes 27 analysts.
How is Regeneron Pharmaceuticals's target upside or downside calculated?
The average target of $863.93 is divided by the recorded price of $790.74, then one is subtracted to produce +9.3%. This does not guarantee a future return.
When was Regeneron Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-10-19. The dataset is valid through 2026-10-26.